1Landis SH, Murray T, Bolden S et al. Cancer statistics,1999. CA Cancer J Clin, 1999,49 (1). 8-31
2Lichtenstein DL,Toth K,Doronin K et al.Functions and mechanisms of action of the adenovirus E3 proteins.Int Rev Immunol,2004,23(1-2):75-111.
3Zou A, Atencio I, Huang WM et al. Overexpression of adenovirus E3 - 11.6K protein induces cell killing by both caspase -dependent and caspase- independent mechanic. Virology, 2004,326 (2): 240-249
4Ikeda K, Ichikawa T, Wakimoto H et al. Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses. Nat Med, 1999; 5(8) : 881 - 887
5Jacohs A, Tjuvajev JG, Dubrovin M et al. Positron emission tomograpby- based imaging of transgene expression mediated by replication- conditional, oncolytic herpes simplex virus type 1 mutant vectors it. vivo. Cancer Res, 2001; 61 (7):2983-2995
6Nemunaitis J, Khuri F, Ganly I et al. Phase Ⅱ trial of intratumoral administration of ONYX - 015, a replicati on selective adenovirus, in patients with refractory head and neck cancer.J Clin Oncol, 2001; 19 (2): 289-298
7Motoi F, Sunamura M, Ding L et al. Effective gene therapy for pancreatic cancer by cytokines by restricted replication-competent adenovirus. Hum Gene Ther, 2000; 11(2): 223-235
8Kurihara T, Broush DE, Kovesdi I et al. Selectivity of a replication- competent adenovirus for human breast carcinoma cells expressing the MUC1 antigen. J Clin Invest, 2000; 106(6) : 763-771
9Goldstein DJ, Weller SK. Factor (s) present in herpes simplex vires type I - infected cells can compensate for the loss of the large subunit the viral ribonucleotide reductase: characterization of an ICP6 deletion mutant. Virlolgy, 1988; 166(1): 41-51
10Kasuya H, Nishiyama Y, Nomoto S et al. Intraperitoneal delivery of hrR3 and gancidovir prolongs survival in mice with disseminated pancreatic cancer. J Surg Oneol, 1999; 72(3) : 136-141
